Matinas Biopharma Holdings Inc. (MTNB)
MTNB trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2023-12-31, https://www.sec.gov/Archives/edgar/data/1582554/000164117225004882/0001641172-25-004882-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2023-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | MTNB on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2017 |
| SEC CIK | 0001582554 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2023
| Line | Value |
|---|---|
| Revenue | $1.1M |
| Net income | -$22.9M |
| Operating income | -$23.8M |
| Net margin | -2093.2% |
| Operating margin | -2168.4% |
| Revenue growth | -65.6% |
| Cash | $4.8M |
| Total assets | $25.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "As a result, substantial doubt exists about the Company's ability to continue as a going concern." | 10-Q 2026-08-13 |
| Cash and burn | $761K cash; operating cash flow -$1.6M a quarter. | Report 2026-06-30 |
| Shares outstanding | 979,520 (2026-08-10); 5,086,985 a year earlier; 217,264,526 three years earlier. 3y figure adjusted for splits (1-for-50 overall). | Cover page 2026-08-10 |
| Reverse splits, 3 years | 2; latest 1-for-15 on 2026-09-28 | Source 2026-09-28 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-06-16 |
| Exchange deficiency notices, 12 months | 3 (8-K item 3.01) | 8-K 2026-09-04 |
| Auditor | EisnerAmper LLP, Iselin, New Jersey, United States | PCAOB Form AP 2026-04-01 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$1.3M | -$1.8M | $761K | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | Not filed | -$1.9M | -$1.6M | $2.4M | No debt tags | Needs four quarters | 10-Q 2026-05-08 |
| Q4 2025 2025-12-31 | Not filed | -$1.9M | -$1.5M | $4.0M | No debt tags | Needs four quarters | 10-K 2026-03-31 |
| Q3 2025 2025-09-30 | Not filed | -$1.5M | -$1.5M | $5.4M | No debt tags | Needs four quarters | 10-Q 2025-11-10 |
| Q2 2025 2025-06-30 | Not filed | -$5.2M | -$2.0M | $6.5M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | Not filed | -$1.7M | -$2.0M | $6.9M | No debt tags | Needs four quarters | 10-Q 2026-05-08 |
| Q4 2024 2024-12-31 | Not filed | -$8.4M | -$3.5M | $7.3M | No debt tags | Needs four quarters | 10-K 2026-03-31 |
| Q3 2024 2024-09-30 | Not filed | -$4.3M | -$3.5M | $10.3M | No debt tags | Needs four quarters | 10-Q 2025-11-10 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B7 | 2026-06-22 |
| Latest annual report | 10-K | 2026-03-31 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report | 8-K | 2026-11-03 |
| Latest proxy | DEF 14A | 2025-05-12 |
Source: SEC EDGAR submissions feed, 577 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -24.4% |
| 1 month | -64.0% |
| 3 months | -74.2% |
| Year to date | +53.6% |
| 1 year | -25.6% |
| From 52-week high | -93.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| OGEN | Oragenics Inc. | $0.1980 | -1.49% | $893K |
| SPRC | SciSparc Ltd. | $0.3307 | -10.62% | $815K |
| GOVX | GeoVax Labs Inc. | $2.02 | +18.48% | $1.1M |
| BDRX | Biodexa Pharmaceuticals plc American Depositary Shs | $2.24 | -6.28% | $1.2M |
| ELAB | PMGC Holdings Inc. | $1.66 | +5.06% | $1.3M |
| KAPA | Kairos Pharma Ltd. | $0.4069 | -10.30% | $1.4M |
| APVO | Aptevo Therapeutics Inc. | $0.5486 | -7.66% | $1.5M |
| LABT | Lakewood-Amedex Biotherapeutics Inc. | $0.2194 | -22.31% | $520K |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier